Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly

Bruce E. Hayward, …, Alain Enjalbert, David T. Bonthron


Approximately 40% of growth hormone–secreting pituitary adenomas have somatic mutations in the GNAS1 gene (the so-called gsp oncogene). These mutations at codon 201 or codon 227 constitutively activate the α subunit of the adenylate cyclase–stimulating G protein Gs. GNAS1 is subject to a complex pattern of genomic imprinting, its various promoters directing the production of maternally, paternally, and biallelically derived gene products. Transcripts encoding Gsα are biallelically derived in most human tissues. Despite this, we show here that in 21 out of 22 gsp-positive somatotroph adenomas, the mutation had occurred on the maternal allele. To investigate the reason for this allelic bias, we also analyzed GNAS1 imprinting in the normal adult pituitary and found that Gsα is monoallelically expressed from the maternal allele in this tissue. We further show that this monoallelic expression of Gsα is frequently relaxed in somatotroph tumors, both in those that have gsp mutations and in those that do not. These findings imply a possible role for loss of Gsα imprinting during pituitary somatotroph tumorigenesis and also suggest that Gsα imprinting is regulated separately from that of the other GNAS1 products, NESP55 and XLαs, imprinting of which is retained in these tumors.

Find the latest version:

http://jci.me/11887-pdf
Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly

Bruce E. Hayward,1 Anne Barlier,2 Márta Korbonits,3 Ashley B. Grossman,3 Philippe Jacquet,4 Alain Enjalbert,2 and David T. Bonthron1

1Molecular Medicine Unit, University of Leeds, Leeds, United Kingdom
2Laboratoire Interactions Cellulaires Neuroendocriniennes, Institut Jean-Roche, Faculté de Médecine Nord, Marseille, France
3Department of Endocrinology, St. Bartholomew’s Hospital, London, United Kingdom
4Service d’Endocrinologie, Centre Hospitalo-Universitaire Timone, Marseille, France

Address correspondence to: David T. Bonthron, Molecular Medicine Unit, University of Leeds, St. James’s University Hospital, Leeds LS9 7TF, United Kingdom. Phone: 44-113-206-5679; Fax: 44-113-244-4475; E-mail: D.T.Bonthron@leeds.ac.uk.

Received for publication November 30, 2000, and accepted in revised form February 12, 2001.

Approximately 40% of growth hormone–secreting pituitary adenomas have somatic mutations in the GNAS1 gene (the so-called gsp oncogene). These mutations at codon 201 or codon 227 constitutively activate the α subunit of the adenylate cyclase–stimulating G protein, Gs. GNAS1 is subject to a complex pattern of genomic imprinting, its various promoters directing the production of maternally, paternally, and biallelically derived gene products. Transcripts encoding Gsα are biallelically derived in most human tissues. Despite this, we show here that in 21 out of 22 gsp-positive somatotroph adenomas, the mutation had occurred on the maternal allele. To investigate the reason for this allelic bias, we also analyzed GNAS1 imprinting in the normal adult pituitary and found that Gsα is monoallelically expressed from the maternal allele in this tissue. We further show that this monoallelic expression of Gsα is frequently relaxed in somatotroph tumors, both in those that have gsp mutations and in those that do not. These findings imply a possible role for loss of Gsα imprinting during pituitary somatotroph tumorigenesis and also suggest that Gsα imprinting is regulated separately from that of the other GNAS1 products, NESP55 and XLαs, imprinting of which is retained in these tumors.


Introduction

The GNAS1 gene on chromosome 20q13 encodes the α subunit of the heterotrimeric guanosine 5’triphosphate–binding (GTP-binding) protein, Gs. Gs couples hormonal stimulation of various cell-surface receptors to the activation of adenylate cyclase. A number of endocrine syndromes are caused by heterozygous mutations that affect Gsα. McCune-Albright syndrome (polystotic fibrous dysplasia, skin hyperpigmentation, and autonomous endocrine hyperfunction) results from somatic mosaicism for a codon 201 mutation, which constitutively activates Gsα by impairing its intrinsic GTPase activity (1). Codon 201 mutations are also found in some endocrine tumors (2) (see below).

In contrast, germline mutations that inactivate Gsα result in the autosomal dominant syndrome Albright’s hereditary osteodystrophy (AHO; characterized by short stature, brachydactyly, and subcutaneous calcification) (3, 4). However, when such mutations are maternally inherited, in addition to AHO, resistance to the peripheral action of several hormones, notably parathyroid hormone (PTH), results (pseudohypoparathyroidism type 1a; PHP-1a). It was this parental origin effect in AHO/PHP that first suggested that GNAS1 might be an imprinted gene (5).

Despite this indirect evidence for Gsα imprinting, in both AHO and PHP-1a the activity of Gsα in erythrocytes is 50% of normal (6, 7), and RNA studies of several human fetal tissues showed biallelic GNAS1 expression (8). It is therefore believed that Gsα is monoallelically expressed only in a few sites, particularly the proximal renal tubule, the main PTH target tissue. This would be consistent with the fact that in PHP-1a patients, renal cAMP response to PTH is absent or severely impaired (9), suggesting target cell Gsα levels much less than the 50% seen in erythrocytes.

Molecular studies have shown that both human GNAS1 and murine Gnas are indeed imprinted, but in a highly complex way. In addition to Gsα, GNAS1 encodes two other proteins, extra-large αs (XLαs) and 55-kDa neuroendocrine secretory protein (NESP55). All three mRNA species include exons 2–13, spliced in each case to a distinct first exon. NESP55 transcripts are maternal, while XLαs transcripts, initiating 14 kb further downstream, are paternal (10, 11). A spliced, paternally expressed, noncoding antisense transcript arises approximately 2.5 kb upstream of XLαs and traverses the NESP55 exon (12). Gsα transcripts, initiating at exon 1, approximately 37 kb downstream of XLαs, are biallelic. Finally, a fourth sense promoter, approximately 2 kb upstream of exon 1, directs expression of paternal transcripts that are probably not translated, since they contain an alternative first exon (1A or A/B) lacking an initiation codon (13–15).

In humans, monoallelic expression of Gsα transcripts has not been demonstrated. In the mouse, though, Gsα does appear to be predominantly maternal in origin in renal cortex and in brown and white fat. In these tissues, Gsα protein and mRNA levels are much lower in mice with a het-
erozygous knockout mutation of the maternal Gnas allele, compared with those with a paternal knockout (16).

While Gαs is ubiquitous, NESP55 and XLαs are highly expressed only in certain neurosecretory tissues, including pituitary (17, 18). XLαs, like Gαs, can bind Gβγ subunits and activate adenylate cyclase (17, 19), but a hormone receptor able to activate XLαs has not been identified. The function of NESP55 is unclear; it was originally suggested to be the proteolytic precursor for certain bioactive peptides (20).

Approximately 40% of pituitary somatotroph adenomas contain heterozygous mutations in GNAS1 that constitutively activate Gαs by substitutions at arginine 201 (R201) or glutamine 227 (Q227) (2, 21–23). Less frequently, the same mutations occur in thyroid tumors (24), Leydig cell tumors of the ovary and testis (25), and tumors of the ovary and testis (25), in thyroid tumors (24), Leydig cell tumors of the ovary and testis (25), and tumors of the ovary and testis (25), in thyroid tumors (24), Leydig cell tumors of the ovary and testis (25), and tumors of the ovary and testis (25).

Methods
Pituitary adenomas were obtained at transssphenoidal surgery. They were classified using clinical and biochemical findings and immunocytochemical and morphological data, including absence of contamination with normal pituitary (31). Normal human pituitary autopsy specimens were used as controls. Somatotroph adenomas were tested for gsp mutations as described (32). From the group of gsp somatotroph tumors and nonfunctioning adenomas, only those heterozygous at the exon 5 polymorphism were selected (see Results).

Institutional approval was received from the Ethics Committees of the University of Aix-Marseilles and St. Bartholomew’s Hospital, and informed consent was received from each patient.

Total RNA was isolated using the SV kit (Promega Corp., Madison, Wisconsin, USA) or Tri-Reagent (Sigma Chemical Co., St. Louis, Missouri, USA) or the ChemiImager 4400 system (Alpha Innotech Corp., San Leandro, California, USA).

Results
Gαs encoding transcripts are monoallelically expressed in the normal pituitary. We identified four adult pituitary heterozygous for the exon 5 polymorphism (at codon 131 of Gαs). RT-PCRs were performed, each using the same downstream primer in exon 10 paired with a primer specific for one of the four alternative first exons. These reactions selectively amplify GNAS1 transcripts specific for one of the three protein-coding mRNAs (NESP55, XLαs, or Gαs) or the noncoding 1A transcript.

Figure 1 shows the sequence across the polymorphic site of cDNAs from two of these samples. NESP55 and XLαs are expressed from opposite alleles, as shown previously in a range of

---

**Figure 1**
Imprinting of GNAS1 transcripts in normal human pituitary. Sequences are shown for each of the four GNAS1 transcript types (Gαs, exon 1A, XLαs, and NESP55) across the site of the exon 5 A/G polymorphism (reverse strand). Results from two normal pituitaries (HN1 and HN3) are shown. In each case the polymorphic residue is indicated by an arrow. The Gαs transcripts are exclusively (HN3) or predominantly (HN1) maternal in origin, i.e., derived from the NESP55-expressing chromosome.
human fetal tissues, in all of which NESP55 is maternally and XLαs paternally derived (11). Exon 1A transcripts were shown recently to be paternally expressed in blood cells of two adults (15). We found similar paternal-specific expression of 1A transcripts in a range of first-trimester fetal tissues (data not shown). Figure 1 shows that the same is also true of adult pituitary.

Examining Gsα transcripts, however, we found that in contrast to the biallelic expression seen in all human tissues examined previously, in the pituitary these transcripts are monoallelic. In each case, the expressed allele is the same as that represented in NESP55 transcripts. XLαs and exon 1A transcripts, in contrast, contain only the opposite allele. These results suggest that in the pituitary, Gsα transcripts, like NESP55, are derived from the maternal allele. The same result was obtained in all four adult pituitary cDNA samples; the maximum proportion of paternal Gsα transcript in any of these samples was 14%.

Somatic activating mutations in somatotroph adenomas occur on the maternal allele. Codons R201 and Q227, the sites of the gsp mutations, lie in exons 8 and 9 and hence are present in the XLαs and NESP55, as well as the Gsα transcripts. Examination of maternal NESP55 and paternal XLαs transcripts for the presence of the gsp mutation should therefore permit the inference of which parental allele carries the mutation.

We examined 22 gsp+ adenomas in this way, including examples with mutations at codons 201 and 227, and also different mutations at each codon. From each tumor, we generated three RT-PCR products (specific for Gsα, XLαs, or NESP55) and sequenced across the gsp mutation site (Figure 2a). In 21 cases (15 R201C, one R201S, one R201H, three Q227L, and one Q227R) the gsp mutation was present in the NESP55 but not the XLαs transcript. This suggests that in somatotroph adenomas, oncogenic gsp mutations virtually always occur on the maternal allele.

In a single adenoma, the mutation (R201H) was found in XLαs (and 1A) transcripts, but not in NESP55 transcripts, suggesting it had occurred on the paternal allele. This mutation creates a NlaIII restriction site. NlaIII digestion of the RT-PCR products was performed to verify the sequencing result, confirming the presence of the mutation on the XLαs but not the NESP55 transcript (not shown). The other R201H adenoma, however, had the mutation on the maternal allele (also verified by NlaIII digests), indicating that there is nothing peculiar to the R201H mutation that requires it to occur on the paternal chromosome.

**Figure 2**

(a) Sequences across codon 201 of the three protein-coding GNAS1 transcripts (Gsα, XLαs, and NESP55) in two R201C gsp+ adenomas (A103, A106). In both examples, the normal allele CGT is expressed from the paternal (XLαs) chromosome, while only the mutated allele TGT (arrow) is represented in the maternal NESP55 transcripts. (b) Sequence across codon 201 (normally CGT) of the Gsα transcript in six gsp+ adenomas, illustrating the variation in relative expression level of the two Gsα alleles. All these adenomas carry the gsp mutation on the maternal allele, apart from NB89, which has the gsp mutation on the paternal allele. In each case, the mutant allele is indicated by an arrow.
Dysregulated imprinting of Gsα transcripts in somatotroph tumors. In gsp+ pituitary tumors, the mutant is usually more abundant than the normal transcript (34). Previously, this has been attributed to a proliferative advantage from high expression of a dominant oncogene. However, a simpler explanation is that gsp mutations occur on the more highly expressed maternal Gsα allele. Figure 2b shows that among gsp+ tumors the ratio of mutant to normal Gsα transcript is quite variable. However, none of our 22 adenomas expressed solely mutant Gsα, even although most showed a bias in favor of the mutant Gsα transcript. This implies that although in most tumors transcription of Gsα from the maternal chromosome remains predominant, there is relaxation of the monoallelic expression pattern, at least in some. We addressed this point further in the context of gsp− somatotroph adenomas.

Sixty percent of somatotroph adenomas are gsp negative (gsp−), and the genetic events involved in their development are largely unknown. In several types of tumor relaxation of IGF2/H19 imprinting occurs (35–37). We therefore wondered whether altered GNAS1 imprinting might be a factor in the pathogenesis of gsp− somatotroph tumors. We examined 19 gsp− adenomas that were heterozygous at the exon 5 polymorphism. Figure 3a shows typical examples of the Gsα transcript sequences. The allelic contributions to Gsα expression vary considerably, ranging from exclusively maternal (e.g., A75) to approximately equal (e.g., 368).

A semiquantitative index of this variability was derived. To control for uneven sample loading, we normalized the intensity of the polymorphic band to that of four neighboring bands in the same lane and then calculated the paternal contribution as a proportion of the sum of the normalized values for the two alleles. (The maternal or paternal allele assignment was based on analysis of NESP55 and XLαs transcripts, as before.) In addition to 19 gsp− somatotroph tumors, for comparison we analyzed the four heterozygous normal adult pituitaries and five nonfunctioning pituitary adenomas. Although there is wide variation among the gsp− somatotroph tumors, for comparison we analyzed the four heterozygous normal adult pituitaries and five nonfunctioning pituitary adenomas. Although there is wide variation among the gsp− somatotroph tumors, a substantial number shows a much greater proportion of paternally derived Gsα than is seen in either the normal samples or the nonfunctioning tumors (Figure 3b). In the normal pituitaries, Gsα expression was either exclusively from or very strongly biased toward the maternal allele. In contrast, in almost two-thirds of gsp− adenomas, Gsα expression was approximately biallelic (paternal proportion 0.3–0.7).

As judged from codon 201 or 227 analysis, Gsα expression was also biallelic in several of the 22 gsp− adenomas (e.g., Figure 2b, tumors A103, A84, NB89). Thus there appears to be relaxation of Gsα imprinting both in gsp+ and gsp− somatotroph tumors. This loss of imprinting may therefore be a secondary feature of adenoma progression. We have shown previously that the GNAS1 transcript levels in gsp− somatotroph adenomas are more variable than in gsp+ adenomas (38). It is possible that part of that variability could be due to relaxation of Gsα imprinting control, resulting in an increase in Gsα transcript.

Discussion
We have found that in normal human pituitary, unlike most tissues, Gsα is monoallelically derived. Furthermore, this imprinted expression pattern is relaxed in a substantial proportion of growth hormone–secreting (GH-secreting) adenomas. In contrast, the opposing monoallelic expression patterns of
not invariable and is therefore unlikely to be required for tumor development. It is more likely that the higher gsp expression simply reflects the fact that the mutations occur on the maternal allele, which is normally expressed at a higher level in the pituitary. Presumably, a gsp mutation on a paternal allele would be silent in most cases.

Nonetheless, all gsp tumors do express some Gsα (often considerably) from the (nonmutated) paternal allele. This could reflect either an absolute need for some normal Gsα function within the cell or a secondary relaxation of imprinting as part of the tumorigenic process. In support of the latter interpretation is our finding that a similar relaxation of Gsα imprinting is also seen at least as frequently in gsp tumors. Therefore, for gsp tumors we favor a model in which the monoallelic origin of Gsα in normal pituitary dictates that the initial gsp mutation must occur on a maternal allele in order to have a phenotypic effect, but that during subsequent tumor growth this monoallelic expression pattern is lost. As a caveat, it is not known whether the gsp+ and normal mRNAs are equally stable. If gsp+ transcripts were less stable, then the steady-state preponderance of maternal (mutated) over paternal (normal) mRNAs would be less pronounced than in normal cells. Nonetheless, such a mechanism would not easily explain the variability in maternal/paternal ratio shown in Figure 2b and also cannot explain the apparent relaxation of imprinting in gsp tumors.

Acknowledgments

This work was supported by the Wellcome Trust (grant number 053701).